Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Albireo Pharma's Average Total Inventories for the quarter that ended in Sep. 2022 was €2.58 Mil. Albireo Pharma's Revenue for the
three
months ended in Sep. 2022 was €9.93 Mil.
Albireo Pharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.26.
Albireo Pharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022
increased
from Jun. 2022 (0.23) to Jun. 2022 (0.26)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Albireo Pharma's Days Inventory for the
three
months ended in Sep. 2022 was 381.17.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Albireo Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.24.
Albireo Pharma Inventory-to-Revenue Historical Data
The historical data trend for Albireo Pharma's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Albireo Pharma's Inventory-to-Revenue
For the Biotechnology subindustry, Albireo Pharma's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Albireo Pharma's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Albireo Pharma's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Albireo Pharma's Inventory-to-Revenue falls into.
Albireo Pharma Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Albireo Pharma's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Albireo Pharma's Days Inventory for the
three
months ended in Sep. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albireo Pharma Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Albireo Pharma's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:BDQM has been successfully added to your 